15 Summary 16 Recurrence and clustering of somatic mutations (hotspots) in cancer genomes may indicate 17 positive selection and involvement in tumorigenesis. MutSpot performs genome-wide 18 inference of mutation hotspots in non-coding and regulatory DNA of cancer genomes. 19
Cancer is a genetic disease arising from (driver) mutations that give cancer cells a selective 35 advantage to proliferate and invade. Early cancer genomics studies have mainly focused on 36 the protein-coding regions of the genome. However, even with thousands of cancer exomes 37 sequenced in the past decade, identification of putative driver mutations in the coding 38 regions has still not saturated in many cancer types (Chang, et al., 2016; Lawrence, et al., 39 2014) . Importantly, mutations in the non-coding DNA that constitutes the other 98% of the 40 human genome is even less explored. Tumor whole genome sequencing is however gaining 41 popularity and a recent study of over 2,500 tumor whole genomes by the ICGC/TCGA Pan-42
Cancer Analysis of Whole Genomes Network (PCAWG) estimated that up to 25% of all tumors 43 harbor non-coding driver mutations (Sabarinathan, et al., 2017) . There is therefore a pressing 44 need to develop statistical methods that can leverage these large datasets to predict driver 45 mutations in the non-coding DNA. 46
Current tools designed to identify non-coding drivers are based on mutation recurrence 47 within regulatory elements (Juul, et al., 2017; Lochovsky, et al., 2015) , predicted functional 48 impact of somatic mutations (Mularoni, et al., 2016) , or a combination of these approaches 49 (Dhingra, et al., 2017; Hornshoj, et al., 2018) . However, existing methods are designed to 50 explore mutations within defined regulatory regions, such as promoters, enhancers or UTRs, 51 therefore ignoring the rest of the non-coding genome. As such, a typical non-coding cancer 52 driver detection method evaluates less than 5% of the 3 million bases sequenced in a WGS 53 experiment for signs of positive selection. Furthermore, by restricting the analysis to 54 annotated regulatory regions, current tools will miss non-coding drivers that create de novo 55 regulatory elements in regions of unannotated DNA. For example, non-coding mutation 56 hotspots upstream of TAL1 and LMO1 in T-cell acute lymphoblastic leukemia lead to the 57 formation of de novo MYB binding sites that drives the over-expression of TAL1 and LMO1 58 oncogenes (Hu, et al., 2017; Mansour, et al., 2014) . Here, we present MutSpot, an R package 59 that systematically and unbiasedly scans the entire genome for mutation hotspots with 60 statistical evidence of positive selection. 61 replication timing, and epigenomic features (Guo, et al., 2018) (Fig. 1a) . Separate background 66 mutation models are built for single nucleotide variants (SNVs) and small insertions and 67 deletions (indels), as they arise from different mutational processes. Local nucleotide context 68 features are automatically computed by MutSpot based on the list of mutations provided by 69 the user. For SNVs, sequence features include the nucleotide type (A/T or C/G), and tri-70 nucleotide (1bp flanks) and penta-nucleotide (2bp flanks) contexts of each mutation. For 71 indels, sequence features include the presence of poly-A, poly-T, poly-G and poly-C sequences 72 at the indel sites. MutSpot uses 135 default epigenetic features including transcription factor 73 binding profiles from ENCODE (Zerbino, et al., 2015) , the mean replication timing profile of 74 13 ENCODE cell lines (Hansen, et al., 2010) , and predicted APOBEC editing sites that could 75 drive passenger hotspots (Buisson, et al., 2019) . Additional epigenomic features can be 76 provided in the bigwig or bed format. MutSpot also calculates the local mutation rate in 100kb 77 genomic bins to correct for additional unexplained regional variation in mutation rates. The 78 most predictive features of mutation probabilities are selected by a LASSO logistic regression 79 model (see Supplementary Methods) . To account for inter-patient heterogeneity, MutSpot 80 corrects for the mutation burden of individual tumors. Additional patient specific features 81 such as mutation signatures and cancer subtypes can also be integrated into the model. 82
Finally, MutSpot fits a logistic regression model over all positions in the genome to estimate 83 patient-and position-specific background mutation probabilities. 84
To identify mutation hotspots, MutSpot evaluates the mutation recurrence for l-bp 85 regions genome-wide with at least n mutations (default l=21, n=2). The p-value of mutation 86 recurrence is computed using a Poisson binomial model that accounts for varying mutation 87 rates across different patient tumors (Guo, et al., 2018; Melton, et al., 2015) . As mutation 88 hotspot detection can be sensitive to recurrent artifacts, MutSpot excludes problematic 89 regions, such as poorly mappable regions and immunoglobin loci, from the analysis. 90
91

Application examples 92
MutSpot can be used to detect mutation hotpots either genome-wide or in user defined 93 regions. In the genome-wide discovery mode, MutSpot fits a genomic background model and 94 scans for mutation hotspots across the whole genome. In the regional discovery mode, comprehensive scan of the entire genome, the regional mode can be advantageous when the 98 mutational processes in the regions of interest are very different from the genomic 99 background. To demonstrate the utility of the regional analysis, we ran MutSpot on 168 non-100 hypermutated gastric cancer whole genomes to detect SNV hotspots 1) genome-wide and 2) 101 in regions comprising CTCF binding sites (CBS) (Guo, et al., 2018) . In each analysis, MutSpot 102 outputs a Manhattan plot of the detected hotspots and a barplot of the Z-values (quantifying 103 association with mutation rate) of the selected features in the fitted background model (Fig.  104   1b and c) . CBSs are known to be hypermutated in gastrointestinal cancers, with a distinct 105 mutation spectrum enriched in A>G and A>C substitutions (Guo, et al., 2018; Katainen, et al., 106 2015) . In the genomic background mutation model, CpG dinucleotides, individual tumor 107 mutation counts and local mutation rate are among the top predictors of mutation probability. 108
On the other hand, consistent with the current knowledge, MutSpot identifies AA 109 dinucleotide as the most important predictor of mutation probability in the CBS-specific 110 model. 24 mutation hotspots at CBSs are identified in the genome-wide model, however, only 111 8 remains significant in the CBS-specific model that corrects for the elevated background 112 mutation rate and unique mutation spectrum at CBSs. 113
As it can be computationally expensive to fit genome-wide models with multiple 114 covariates, sparse matrices were implemented to minimize memory usage and a multi-115 threading option is available to reduce the compute time. MutSpot takes less than 3 hours 116 on a 4 core machine for genome-wide hotspot discovery in 200 tumors, and it can be scaled 117 up to process thousands of tumors on a standard work station (Supplementary Fig. 1) . 118 119 Discussion 120
While most existing non-coding driver discovery tools consider sets of predefined features in 121 the background mutation model, MutSpot offers the flexibility to incorporate any genomic or 122 clinical covariate into the background model. This allows the user to include tissue specific 123 epigenetic features for the cancer type of interest, and newly discovered mutational biases 124 into the background mutation model. As our current knowledge of the mutational processes 125 and biases is far from complete, new insights in the processes underlying somatic mutations 126 will further improve the accuracy of hotspot detection. 127
In conclusion, MutSpot is a user friendly tool for end-to-end non-coding mutation becomes available, MutSpot can facilitate the discovery of novel drivers in the non-coding Figure legends 
